Related Blog Posts from the Wikinvest Wire

Amgen (AMGN)   Subscribe to Amgen (AMGN) content from the Wikinvest Wire
 » Back to Amgen (NASDAQ:AMGN) Stock Page

  

9/22/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Submits Biologics License Application for Inves... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 22, 2014 /PRNewswire/ -- Amgen (AMGN) today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval for its investigational bispecific T cell engager (BiTE®) antibody construct, blinatumomab. The BLA is for the treatment of adults with Philadelphia-negative (Ph-) [...]

9/15/14Company Update (NASDAQ:AMGN): Amgen Announces Results From Several New Exploratory Analyses Evalu... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 15, 2014 /PRNewswire/ -- Amgen (AMGN) today announced results from a new exploratory analysis of the open-label extension study of the pivotal Phase 3 fracture trial, which found that treatment with Prolia® (denosumab) for eight years enabled a substantial proportion of women with osteoporosis to achieve non-osteoporotic [...]

9/10/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces 23 Abstracts To Be Presented At The Ame... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 10, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will present data from multiple Prolia® (denosumab) and romosozumab study analyses at the American Society for Bone and Mineral Research (ASBMR) 2014 Annual Meeting being held in Houston, Sept. 12-15, 2014. The data that will be presented [...]

9/2/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Submits Marketing Authorization Application For T... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Sept. 2, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) via the centralized procedure for talimogene laherparepvec seeking approval for the treatment of adults with melanoma that is regionally or distantly metastatic. Talimogene laherparepvec is [...]

8/28/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen submits U.S. application to sell cholesterol-fi... (Jutia Group)

[Reuters] - Amgen Inc said it submitted an application to the U.S. Food and Drug Administration to market its cholesterol-lowering drug, evolocumab. The injectable drug works by blocking PCSK9, a naturally occurring ... Read more on this. Amgen Inc. (AMGN), valued at $105.54B, started the session at $137.65.   Looking [...]

8/27/14Stock Update: Amgen Inc (NASDAQ:AMGN) – FDA Grants Amgen Priority Review Designation For Ivabra... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Aug. 27, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the [...]

8/21/14Market Update: Amgen Inc (NASDAQ:AMGN) – Lilly psoriasis drug impresses; battle nears with Amge... (Jutia Group)

[Reuters] - An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. Based on favorable results from Phase III trials, Lilly said Thursday it would seek marketing approval in [...]

8/21/14Stock Update: Eli Lilly & Company (NYSE:LLY) – Lilly psoriasis drug impresses; battle nears wit... (Jutia Group)

[Reuters] - An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG. Based on favorable results from Phase III trials, Lilly said Thursday it would seek marketing approval in [...]

8/18/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Second... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Aug. 18, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. Read more on this. Amgen [...]

8/13/14Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Issues Voluntary Recall of Aranesp® (darbepoeti... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Aug. 13, 2014 /PRNewswire/ -- Amgen (AMGN) initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies due to the potential presence of cellulose and/or polyester particles observed [...]

8/4/14Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In ... (Jutia Group)

[at noodls] - THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug. 4, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary, Onyx Pharmaceuticals, Inc., today announced that a planned interim analysis demonstrated ... Read more on this. Amgen Inc. (AMGN), currently valued at $96.23B, began trading this morning at $129.21.   [...]

7/31/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Second Quarter 2014 Revenues Increased 11 P... (Jutia Group)

[at noodls] - Amgen's Second Quarter 2014 Revenues Increased 11 Percent To $5.2 Billion And Adjusted Earnings Per Share (EPS) Increased 25 Percent To $2.37 Second Quarter 2014 GAAP EPS Were $2.01 2014 Total Revenues ... Read more on this. Amgen Inc. (AMGN), valued at $96.69B, opened at $128.28.   [...]

7/29/14Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Second Quarter 2014 Revenues Increased 11 Pe... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., July 29, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2014. Key results include: Total revenues increased 11 percent to $5,180 ... Read more on this. Amgen Inc. (AMGN), valued at $93.35B, opened at $122.52.   Today’s [...]

7/25/14Amgen Inc (NASDAQ:AMGN) – Bayer and Onyx Pharmaceuticals Report Phase 3 Trial Results of NEXAVA... (Jutia Group)

[at noodls] - Whippany, NJ and South San Francisco, CA . - Jul 25, 2014 Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary (NASDAQ:AMGN), today announced that an investigational Phase 3 trial of NEXAVAR® ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $92.34B, began trading this [...]

7/24/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 Second Quarter Financia... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., July 24, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its second quarter financial results on Tuesday, July 29, 2014, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and [...]

6/18/14AMGN Named A Top Socially Responsible Dividend Stock (Jutia Group)

Amgen Inc has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 2.1% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like [...]

5/27/14Market Update: Amgen Inc (NASDAQ:AMGN) – Amgen and Onyx Data at ASCO 2014 Highlight Oncology Pi... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., May 27, 2014 /PRNewswire/ -- Amgen (AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced data from several studies of both pipeline and marketed products will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held [...]

5/12/14Amgen Inc (NASDAQ:AMGN) – Amgen Names Steven K. Galson, Senior Vice President, Global Regulator... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., May 12, 2014 /PRNewswire/ -- Amgen (AMGN) today announced the appointment of Steven K. Galson, M.D., M.P.H., to the position of senior vice president, Global Regulatory Affairs and Safety, effective May 19. Galson will report to Sean E. Harper, M.D., executive vice president, Research and Development, and will [...]

5/9/14Amgen Inc (NASDAQ:AMGN) – Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ -- Amgen (AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses. A significantly higher proportion of patients treated with brodalumab achieved a [...]

4/22/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s First Quarter 2014 Revenues Increased 7 Perce... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 22, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2014. Key results include: Total revenues increased 7 percent to $4,521 ... Read more on this. Amgen Inc. (AMGN), valued at $90.07B, opened this morning at $117.24.   [...]

4/17/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 First Quarter Financial... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 17, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close of the U.S. financial markets. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and [...]

4/4/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Provides Update On Phase 3 Study Of Talimogene La... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec for the treatment of unresected stage IIIB, IIIC or IV melanoma compared to treatment [...]

3/26/14Amgen Inc (NASDAQ:AMGN) – Amgen To Webcast Investor Meeting At Upcoming American College of Car... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 26, 2014 /PRNewswire/ -- Amgen (AMGN) will host a webcast investor meeting at the American College of Cardiology's 63rd Annual Scientific Session (ACC.14) in Washington, D.C. on Sunday, March 30, at 7 p.m. EDT. Sean E. Harper, M.D., executive vice president of Research and Development at Amgen, [...]

3/24/14Company Update (NASDAQ:AMGN): Phase 3 Pivotal Data On Amgen’s Novel Investigational Cholesterol... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 24, 2014 /PRNewswire/ -- Amgen (AMGN) today announced that it will present pivotal Phase 3 data from five clinical studies evaluating evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or [...]

3/17/14Company Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase ... (Jutia Group)

[at noodls] - THOUSAND OAKS, Calif., March 17, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 TESLA (Trial Evaluating PCSK9 Antibody in Subjects with LDL Receptor Abnormalities) trial evaluating ... Read more on this. Amgen Inc. (AMGN), valued at $93.62B, started the session at $123.09.   Looking [...]

3/14/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen’s Talimogene Laherparepvec Reduced Size Of Mela... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., March 14, 2014 /PRNewswire/ -- Amgen (AMGN) today announced findings from a pre-specified retrospective analysis of patients with metastatic melanoma that showed talimogene laherparepvec reduced the size of injected tumors and also non-injected tumors that had metastasized to other parts of the body. The analysis recorded tumor-level responses [...]

3/5/14Amgen Inc (NASDAQ:AMGN) | Amgen Announces 2014 Second Quarter Dividend (Jutia Group)

[at noodls] - THOUSAND OAKS, Calif., March 5, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the second quarter of 2014. The dividend will ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $95.27B, started the session [...]

2/21/14Amgen Inc (NASDAQ:AMGN) – Amgen To Present At The RBC Capital Markets’ Global Healthcare Conf... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Feb. 21, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the RBC Capital Markets' Global Healthcare Conference at 4:05 p.m. ET on Wednesday, Feb. 26, 2014, at the New York ... Read more on this. Amgen Inc. (AMGN), with a current value of $93.51B, opened this [...]

1/31/14Amgen Inc (NASDAQ:AMGN) – 2014′s Better Biotech Buy: Biogen Idec, Inc. vs. Amgen, Inc. (Jutia Group)

[at Motley Fool] - Big biotech has surged in the past few years, with Biogen and Amgen among the two leaders in this industry. Which stock looks the best for investors in 2014? Read more on this. Amgen Inc. (AMGN), valued at $90.34B, started trading this morning at $118.55.   [...]

1/30/14Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Positive Top-Line Results From Phase 3 ... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 30, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Phase 3 RUTHERFORD-2 ( R ed U ction of LDL-C with PCSK9 Inhibi T ion in HE te R ozygous F amilial Hyperch ... Read more on this. Amgen Inc. (AMGN), valued at $91.17B, opened at [...]

1/28/14Amgen Inc (NASDAQ:AMGN) – Amgen’s 2013 Revenues Increased 8 Percent To $18.7 Billion And Adju... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 28, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2013. Key results include: For the fourth quarter, total ... Read more on this. Amgen Inc. (AMGN), valued at $91.07B, opened this morning at $118.39.   [...]

1/27/14Company Update: Amgen Inc (NASDAQ:AMGN) – Whisper Number: How Will Amgen’s Stock Move After E... (Jutia Group)

[at Wall St. Cheat Sheet] - Amgen has a 62 percent positive surprise history, having topped the whisper in 32 of the 52 earnings reports for which we have data. Read more on this. Amgen Inc. (AMGN), valued at $89.38B, started trading this morning at $119.50.   During today's session, [...]

1/24/14Amgen Inc (NASDAQ:AMGN) | Amgen: The Best Value In Biotech (Jutia Group)

[at Seeking Alpha] - The biotech industry offers investors an outsize chance to make an above average return on capital in a short period of time. The industries life blood revolves around developing cutting edge remedies ... Read more on this. Amgen Inc. (AMGN), valued at $90.22B, opened this morning at $122.59. [...]

1/23/14Amgen Inc (NASDAQ:AMGN) – What You Need to Know About Amgen’s Oncology Line-Up (Jutia Group)

[at Motley Fool] - Until recently, Amgen’s oncology presence has been somewhat limited. Over the next several years we can expect the California juggernaut to create big waves with these cancer fighting therapies. Read more on this. Amgen Inc. (AMGN), valued at $93.15B, ended session yesterday at $124.37.   Looking [...]

1/16/14Amgen, Inc. (NASDAQ:AMGN) | Will Conservative Guidance Sink This Big Biotech in 2014? (Jutia Group)

[at Motley Fool] - Celgene recently slipped on weaker-than-expected guidance for 2014. Should investors buy the dip? Let’s compare Celgene to its big biotech peers Amgen, Biogen, and Gilead Sciences, to better understand ... Read more on this. Amgen Inc. (AMGN), currently valued at $89.70B, began trading this morning at $118.82.   [...]

1/15/14Amgen, Inc. (NASDAQ:AMGN) – Mass. General, Broad Institute and Amgen Will Work to Discover New ... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 15, 2014 /PRNewswire/ -- Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ:AMGN) announced today that they have launched a strategic collaboration ... Read more on this. Amgen Inc. (AMGN), valued at $88.87B, ended trading at $117.72.   During the trading session, [...]

1/10/14Amgen Inc. (NASDAQ:AMGN) ~ Don’t Underestimate Amgen: Part 1 (Jutia Group)

[at Seeking Alpha] - Although shares of Amgen ( AMGN ) are up over 30% this past year, many analysts and investors continue to underestimate Amgen's potential. These analysts and investors are so enthralled by the immediate ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $89.30B, ended [...]

1/9/14Amgen Inc. (NASDAQ:AMGN) ~ Chief Financial Officer Jonathan M. Peacock to Leave Amgen; Company Ap... (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Jan. 9, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that Jonathan M. Peacock, executive vice president and chief financial officer, is leaving Amgen to pursue broader ... Read more on this. Amgen Inc. (AMGN), with a current value of $89.66B, opened this morning at $116.54.   [...]

1/6/14Stock Update: The Walt Disney Company (NYSE:DIS) – Dividend Portfolio Playoffs Wild Card Game: ... (Jutia Group)

[at Seeking Alpha] - In the first round of the Dividend Portfolio playoffs we have #12 seeded Amgen, Inc. ( AMGN ) taking on #5 seeded Walt Disney Company ( DIS ). Amgen is a global biotech company that discovers, develops, ... Read more on this. The Walt Disney Company (DIS), with a [...]

1/6/14Amgen Inc. (NASDAQ:AMGN) – Dividend Portfolio Playoffs Wild Card Game: Amgen Vs. Disney (Jutia Group)

[at Seeking Alpha] - In the first round of the Dividend Portfolio playoffs we have #12 seeded Amgen, Inc. ( AMGN ) taking on #5 seeded Walt Disney Company ( DIS ). Amgen is a global biotech company that discovers, develops, ... Read more on this. Amgen Inc. (AMGN), valued at $86.09B, started [...]

1/2/14Company Update – Amgen Inc. (NASDAQ:AMGN) – Gilead Sciences: Sovaldi to Boost Shares in 2014,... (Jutia Group)

[at Barrons.com] - Maxim Group's Jason Kolbert upped his target for Gilead Sciences (GILD) today, based on potential sales of Sovaldi. Shares of Gilead gained 104% in 2013, besting Amgen's (AMGN) 35% rise, Regeneron Pharmaceuticals (REGN) ... Read more on this. Amgen Inc. (AMGN), with a current market cap of $87.31B, opened at [...]

12/19/13Amgen Inc. (NASDAQ:AMGN) – Amgen cholesterol drug succeeds in late-stage trial (Jutia Group)

[Reuters] - Amgen Inc said its closely watched experimental cholesterol drug succeeded in reducing the level of bad cholesterol in the blood, compared to a placebo, in a late-stage trial. The data was consistent with the results from a large mid-stage trial that showed the drug, evolocumab, lowered LDL cholesterol by 52 percent after [...]

12/17/13Amgen Inc. (NASDAQ:AMGN) ~ Amgen announces MENDEL-2 Phase 3 trial met co-primary endpoints (Jutia Group)

[theflyonthewall.com] - Amgen announced that the Phase 3 MENDEL-2 trial with evolocumab met its co-primary endpoints, which was the percent reduction from baseline in low-density lipoprotein cholesterol at week 12 and the mean ... Read more on this. Amgen Inc. (AMGN), with a current value of $83.20B, started the session at $112.86. [...]

12/16/13Company Update – Amgen Inc. (NASDAQ:AMGN) – How To YieldBoost Amgen To 4.1% Using Options (Jutia Group)

[at Forbes] - Shareholders of Amgen (NASD: AMGN) looking to boost their income beyond the stock's 1.7% annualized dividend yield can sell the January 2016 covered call at the $150 strike and collect the premium based on the $5.65 bid, which annualizes to an additional 2.4% rate of return against the current stock [...] [...]

12/13/13Stock Update: Amgen Inc. (NASDAQ:AMGN) – Amgen Announces 2014 First Quarter Dividend (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Dec. 13, 2013 /PRNewswire/ -- Amgen (AMGN) announced that its Board of Directors today declared a $0.61 per share dividend for the first quarter of 2014. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative [...]

12/10/13Amgen Inc. (NASDAQ:AMGN) – Amgen To Host Post American Society of Hematology (ASH) Summary Webcast (Jutia Group)

THOUSAND OAKS, Calif., Dec. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president [...]

12/6/13Amgen Inc. (NASDAQ:AMGN) – The International Myeloma Foundation Announces Partnership With Onyx... (Jutia Group)

[Marketwired] - The International Myeloma Foundation -- improving the quality of life of myeloma patients while working toward prevention and a cure -- and Onyx Pharmaceuticals, Inc., an Amgen subsidiary , today announced ... Read more on this. Amgen Inc. (AMGN), currently valued at $86.05B, opened at $115.00.   Looking [...]

12/5/13Amgen Inc. (NASDAQ:AMGN) – Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference (Jutia Group)

[PR Newswire] - THOUSAND OAKS, Calif., Dec. 5, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate at the Oppenheimer 24 th Annual Healthcare Conference on Tuesday, Dec. 10, 2013, at the Crowne Plaza in New York ... Read more on this. Amgen Inc. (AMGN), with a current value of $85.48B, began trading this morning [...]

11/22/13Company Update – Amgen Inc. (NASDAQ:AMGN) – I’m Staying Away From Low Yielding Amgen For Now (Jutia Group)

[at Seeking Alpha] - The last time I wrote about Amgen ( AMGN ) I bought a small batch in it stating that was a good value at the time. Since the last article it actually shot up 7% excluding the dividend (it is up 7.41% including ... Read more on this. Amgen [...]

11/20/13Company Update: Amgen Inc. (NASDAQ:AMGN) – Ahead of the Bell: Amgen’s cholesterol drug (Jutia Group)

[AP] - Amgen said Tuesday that an experimental drug reduced patients' "bad" cholesterol levels by half in a yearlong study. The company said patients who took the drug, called evolocumab, and standard ... Read more on this. Amgen Inc. (AMGN), valued at $87.37B, opened at $115.36. During the trading session, AMGN [...]


Your blog posts can appear here by joining the Wikinvest Wire
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki